Hi everyone,

Bret asked in the comments whether Angiex’s drug AGX101 works for Stage 4 lung cancer patients. AGX101 is in Phase 1 clinical trials and we still have a lot to learn about it. But early results are very promising. I thought I’d copy my answer here. Let me know if there is interest from PHD readers for a webinar to learn more.

Hi Bret,

Yes. AGX101 has potent on-tumor activity against all solid cancers, and so far our best results have been in lung tumors. We’ve dosed 38 patients total and 13 have had lung tumors as target lesions. The number of lung tumors treated is 24 target lesions (i.e. measured in size by the radiologist) and a similar number of non-target lesions. To date those have been metastases from other cancers rather than primary tumors, but it doesn’t really matter whether the tumors are primary or metastatic, they respond the same.

Here is an example. This is a fused PET-CT image with CT on the gray scale and PET in color.

The way our drug works is to attack both the tumor blood vessels and the tumor cells. Eliminating the blood vessels generates a coagulative necrosis that heals by scarring, while killing the tumor cells reduces metabolic activity and prevents spread of any tumor cells out of the tumor. As a result, the “success signal” is stable lesion size on CT with reduction in metabolic activity on FDG-PET. You see that success signal achieved in the linked image.

We believe that at the optimal dosing regimen we may achieve this success signal in all tumors of all solid cancer patients. We’re homing in on that dosing regimen now.

You can write me at one of the emails on the Angiex contact page, https://angiex.com/contact, for more information.

Best, Paul